- A
- Incorrect because MAO (monoamine oxidase) specifically degrades monoamine neurotransmitters (dopamine, serotonin, norepinephrine), not acetylcholine; MAOIs would not increase ACh levels; the enzyme that breaks down ACh is acetylcholinesterase.
- C
- Incorrect because dopamine antagonists block dopamine receptors; they have no direct effect on acetylcholine levels and are not used to treat Alzheimer's disease (which involves acetylcholine deficiency, not dopamine excess).
- D
- Incorrect because there is no clinically established acetylcholine reuptake inhibitor used in the way that SSRIs block serotonin reuptake; acetylcholine clearance from the synapse is primarily accomplished by enzymatic degradation (by acetylcholinesterase), not by reuptake transporters; the correct treatment approach is to block the enzyme.